Agenus (Nasdaq:AGEN) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AGEN Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan Agenus Inc., Amerika Birleşik Devletleri'nde ve uluslararası alanda immüno-onkoloji ürünleri keşfetmekte ve geliştirmektedir.

Şirket hakkında

AGEN temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Ödüller

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 1.7% oranında düşmesi öngörülüyor

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

+ 2 daha fazla risk

Agenus Inc. Rakipler

Assembly Biosciences

NasdaqGS:ASMB

US$94.5m

Coherus BioSciences

NasdaqGM:CHRS

US$119.8m

Elutia

NasdaqCM:ELUT

US$129.1m

Karyopharm Therapeutics

NasdaqGS:KPTI

US$110.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Agenus
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$4.65
52 Haftanın En Yüksek Seviyesi	US$23.20
52 Haftanın En Düşük Seviyesi	US$4.41
Beta	1.36
11 Aylık Değişim	-6.06%
3 Aylık Değişim	-70.15%
1 Yıllık Değişim	-76.98%
33 Yıllık Değişim	-95.88%
5 Yıllık Değişim	-91.36%
Halka arzdan bu yana değişim	-99.94%

Son Haberler & Güncellemeler

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

Recent updates

Agenus: Novel Drugs That Just Are Not Novel

Jul 24

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

May 21

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

May 09

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Mar 29

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Jan 18

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Dec 22

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Nov 09

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Oct 04

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

May 10

Agenus Inc.'s Imminent 1181/Bal Data Release And MiNK IPO Should Lead To Enormous Valuation Gains

Aug 25

Agenus Multiple Value-Adding Events Ahead

Aug 18

Party Time: Brokers Just Made Major Increases To Their Agenus Inc. (NASDAQ:AGEN) Earnings Forecasts

Aug 11

Hissedar Getirileri

	AGEN	US Biotechs	US Pazar
7D	-15.1%	-2.6%	-0.7%
1Y	-77.0%	17.5%	30.3%

Getiri vs. Endüstri: AGEN geçen yıl % 22.1 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: AGEN geçen yıl % 34.1 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AGEN's price volatile compared to industry and market?
AGEN volatility
AGEN Average Weekly Movement	20.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: AGEN hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: AGEN 'nin haftalık oynaklığı ( 21% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1994	389	Garo Armen	www.agenusbio.com

Klinik aşamada bir biyoteknoloji şirketi olan Agenus Inc., Amerika Birleşik Devletleri'nde ve uluslararası alanda immüno-onkoloji ürünleri keşfetmekte ve geliştirmektedir. Şirket, tamamen insani ve insanlaştırılmış monoklonal antikorların tanımlanması için bir antikor ekspresyon platformu olan Retrocyte Display ve görüntüleme teknolojileri sunmaktadır. Saponin bazlı bir aşı adjuvanı olan QS-21 Stimulon adjuvanını geliştirmektedir.

Agenus Inc. Temel Bilgiler Özeti

Agenus'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AGEN temel i̇stati̇sti̇kler
Piyasa değeri	US$105.06m
Kazançlar(TTM)	-US$223.67m
Gelir(TTM)	US$159.63m

0.6x

P/S Oranı

-0.4x

F/K Oranı

AGEN aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AGEN gelir tablosu (TTM)
Gelir	US$159.63m
Gelir Maliyeti	US$199.65m
Brüt Kâr	-US$40.02m
Diğer Giderler	US$183.65m
Kazançlar	-US$223.67m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-10.37
Brüt Marj	-25.07%
Net Kâr Marjı	-140.12%
Borç/Özkaynak Oranı	-6.1%

AGEN uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AGEN Stoklara Genel Bakış

Ödüller

Risk Analizi

Agenus Inc. Rakipler

NasdaqGS:ASMB

US$94.5m

NasdaqGM:CHRS

US$119.8m

NasdaqCM:ELUT

US$129.1m

NasdaqGS:KPTI

US$110.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Recent updates

Rosen Law Firm Announces the Filing of a Class Action Lawsuit Against Agenus Inc

Agenus Inc. Appoints Tom Harrison to Its Board of Directors

Agenus Inc. to Report Q2, 2024 Results on Aug 08, 2024

Agenus: Novel Drugs That Just Are Not Novel

Agenus Inc. Announces End-Of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for Bot/Bal in MSS Colorectal Cancer

Agenus Inc Announces Results from an Investigator-Sponsored Trial (IST) of Botensilimab and Balstilimab (BOT/BALl) in the Neoadjuvant Setting for Colon Cancer

Agenus Inc. Announces Availability of Botensilimab for Clinical Studies

Agenus Appoints Jennifer Buell to Its Board of Directors

There's No Escaping Agenus Inc.'s (NASDAQ:AGEN) Muted Revenues Despite A 102% Share Price Rise

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Consensus revenue estimates fall by 27%

New major risk - Financial position

Analysts Have Lowered Expectations For Agenus Inc. (NASDAQ:AGEN) After Its Latest Results

Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus’ Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Agenus Inc., Annual General Meeting, Jun 11, 2024

Agenus Inc. to Report Q1, 2024 Results on May 07, 2024

New major risk - Share price stability

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Benign Growth For Agenus Inc. (NASDAQ:AGEN) Underpins Stock's 25% Plummet

Consensus revenue estimates increase by 30%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Agenus Inc. to Report Q4, 2023 Results on Mar 14, 2024

Founder recently bought US$324k worth of stock

Agenus: 2024 May Finally Be The Year For A Major Turnaround

Improved Revenues Required Before Agenus Inc. (NASDAQ:AGEN) Shares Find Their Feet

Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

Agenus Receives Notice from Nasdaq Stock Market's Listing Qualifications Department

News Flash: Analysts Just Made A Huge Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 17% to US$6.67

Agenus Inc. to Report Q3, 2023 Results on Nov 07, 2023

Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma

Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas

Now 22% undervalued after recent price drop

Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer

A Look At The Fair Value Of Agenus Inc. (NASDAQ:AGEN)

Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Inc. to Report Q2, 2023 Results on Aug 08, 2023

Agenus' Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer

Industry Analysts Just Made A Notable Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Revenue Forecasts

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Agenus Inc. Announces the Resignation of Wadih Jordan as Director, Effective December 31, 2022

Price target decreased to US$6.33

Insufficient new directors

Agenus Inc. Data At SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant Cancers

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Agenus Inc. to Report Q3, 2022 Results on Nov 08, 2022

Agenus Inc. Announces GSK Disclose Positive Pivotal Phase III Trial Results for Its Respiratory Syncytial Virus Vaccine Candidate

VBI Vaccines, Agenus to examine VBI-1901 + balstilimab combo for glioblastoma

Investor sentiment improved over the past week

Price target decreased to US$6.33

Agenus New Trials Set It Up For The Long Haul